Overview

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2024-12-15
Target enrollment:
Participant gender:
Summary
Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness, UACR, endothelial glycocalyx and global longitudinal strain will be assesed at baseline, 4 and 12 months.
Phase:
NA
Details
Lead Sponsor:
Attikon Hospital
Treatments:
Dipeptidyl-Peptidase IV Inhibitors
dulaglutide